EMA Committee Recommends Indication Extensions for Bexsero and Talzenna
The EMA's CHMP recommended extensions of indication for Bexsero and Talzenna.
Related stories
AstraZeneca Hypertension Drug Recommended for EU Approval
The European Medicines Agency's human-medicines committee recommended AstraZeneca's Baxfendy for approval to treat insufficiently controlled hypertension.
L impact | REGULATION | Nov 13, 2026, 11:47 AM UTC
Merck Combination Wins EU Panel Backing for Advanced Kidney Cancer
An EU panel backed Merck’s Welireg-lenvatinib combination for advanced kidney cancer.
M impact | REGULATION | Nov 13, 2026, 11:35 AM UTC
CHMP Recommends EU Approval of Roche’s Gazyva for Lupus
The European Medicines Agency’s CHMP recommended EU approval of Roche’s Gazyva/Gazyvaro for systemic lupus erythematosus (SLE).
M impact | REGULATION | Nov 13, 2026, 11:30 AM UTC
Irish regulator fines Tinder owner €11 million
Ireland's data protection regulator fined the owner of Tinder €11 million.
M impact | REGULATION | Nov 13, 2026, 11:27 AM UTC
EMA Committee Recommends Steglatro Indication Extension
The EMA’s CHMP recommends extending Steglatro’s therapeutic indication.
L impact | REGULATION | Nov 13, 2026, 11:07 AM UTC
Megaspeed Unit Under Probe in Malaysia Over AI Chip Re-exports
M impact | REGULATION | Nov 13, 2026, 11:02 AM UTC